A UK research team has developed a pioneering blood test that could change the way lung cancer is detected and monitored.

NeXT Personal identifies circulating tumor DNA in 81% of early-stage lung adenocarcinoma cases, offering potential for better disease stratification and outcome prediction. Study: Ultrasensitive ctDNA ...

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), in collaboration with Professor Charles Swanton and his colleagues at London’s Francis Crick Institute and University College London, ...